Oral Octreotide using RaniPill™

Credit: Rani Therapeutics

Update 21st March 2022

Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule. Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development.

Update 4th May 2021

According to Fierce Biotech, Rani Therapeutics has secured $69 million in new funding to move forward with the manufacturing and clinical testing of its “robotic pill”—a small, swallowable capsule that promises to shepherd more delicate drugs past the stomach before releasing them into the bloodstream.

The pill aims to make it easier for a patient to take therapies that typically require an injection or infusion, including treatments for diabetes, arthritis and other diseases.

Currently, the Fierce 15 winner is working with drugmakers Novartis and Takeda to transform their liquid injections into solid pills. 

Rani Therapeutics, a leader in oral biologics, has announced positive results from the Phase I clinical study of its orally-delivered version of octreotide, Octreotide-RP, a drug used in the treatment of acromegaly and neuroendocrine tumors. The Phase I study successfully achieved both its primary and secondary endpoints, demonstrating the safety and tolerability of Octreotide-RP, the RaniPill™ loaded with octreotide, and high oral bioavailability of the biologic drug.  The Phase I clinical study of Octreotide-RP was conducted in Australia with 58 healthy adult volunteers. The test group was comprised of both male and female subjects aged 18 to 55. Of the 58 participants, 52 were treated with Octreotide-RP, while a control group of 6 participants was given an intravenous injection of an identical dose of octreotide. Results of the study demonstrated that the bioavailability of Octreotide-RP was greater than 70%. No serious adverse events were reported for any subject in the study. The plan is to conduct a proper head-to-head study in the coming year and demonstrate equivalence or non-inferiority to the injectable version. The earliest Rani Therapeutics expects the product to be available, assuming all goes well clinically, is 2022.  It’s also of interest that Novartis (Octreotide manufacturer) is said to be a partner in the development, mainly via funding to support clinical trials.

How does it work?

The RaniPill, as it is called, looks like a larger version of a normal pill. When swallowed, it passes through the stomach untouched. The outer covering only dissolves in the less acidic environment of the intestine. When this happens, a tiny balloon inflates and pushes a small needle into the muscular wall of the intestine that injects the drug the pill is carrying. The balloon then deflates and the remains of the pill are excreted. The intestine has no receptors for sharp pain and heals very quickly. “It’s completely pain-free,” says Mir Imran, the head of Rani Therapeutics of San Jose, California. “Not a single subject felt anything.” In addition to oral octreotide, Rani has a pipeline of drugs for the treatment of diabetes, osteoporosis, and rheumatoid arthritis, among other diseases. Rani’s goal is to transform the lives of millions of patients around the globe by replacing painful injections with pills. In addition to the picture below, check out the animated video from Rani Therapeutics – click here

RaniPill™ outlined in red, moving from the stomach to the intestines from the Feb. 2019 successful study without a drug. Photo Credit: PRNewsfoto/Rani Therapeutics

Further reading:

1.  Click here for Rani Therapeutics website.
2.  Read the article in the New Scientist – click here.
3.  For other delivery mechanisms in the pipeline for somatostatin analogues, please click here.
4.  Clinical Trial Document – click here.

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 


Thanks for reading.


Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


3 thoughts on “Oral Octreotide using RaniPill™

  • Brent

    I couldn’t find whether the proposed treatment for NETs would be daily, LAR, etc? Any further information on this and what side effects they are reporting that are “not serious” is appreciated. Thank you as always for your enlightening reporting.

    • when you look at the dose used in trial it compares to daily octreotide inferring it’s a tablet per day. However, my interpretation of the documents available so far, is that it’s designed as a replacement for both with 28 tablets replacing Sandostatin LAR. Long acting somatostatin analogues operate on a ‘depot’ system and clearly this method of administration is basically a form of topping up, unable to work in a depot fashion.

I love comments - feel free!

%d bloggers like this:
Verified by MonsterInsights